Scarica l'app Stockscreener
16.40
3.76%
-0.64
Dopo l'orario di chiusura:
16.47
0.07
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup - TipRanks
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Mizuho Raises Price Target | SRPT Stock News - GuruFocus
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Miz - GuruFocus
Sarepta (SRPT) executive has shares withheld to pay RSU tax - Stock Titan
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Sarepta (SRPT) COO has 1,619 shares withheld to cover RSU taxes - Stock Titan
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Sarepta (NASDAQ:SRPT) Healthcare Tech Buzz In Nasdaq Composite - Kalkine Media
Citigroup Raises Price Target for SRPT but Maintains Sell Rating - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Given New $9.00 Price Target at Citigroup - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Market Sentiment Tied To Nasdaq Futures - Kalkine Media
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Why Is uniQure Stock Skyrocketing Monday? - Benzinga
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - MSN
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN
Assessing Sarepta Therapeutics (SRPT) Valuation After A Difficult Year For Shareholders - Yahoo Finance
Sarepta Therapeutics Stock Pre-Market (+4.7%): Rebounds With Market on Easing Geopolitical Fears - Trefis
SRPT Earnings History & Surprises | EPS & Revenue Results | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Stock Pre-Market (+4.7%): Sector Read-Across Ahead of Key Medical Conferences - Trefis
Biopharma’s recent string of CEO splits - Pharma Voice
A Look At Sarepta Therapeutics (SRPT) Valuation After Elevidys Launch Updates And Recovery Story Analyst Commentary - Sahm
Sarepta Therapeutics (SRPT) Is Down 7.0% After CEO Retirement Plan And ELEVIDYS Japan Launch NewsHas The Bull Case Changed? - Sahm
(SRPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026 - Meyka
Sarepta (SRPT) COO Estepan reports PSU vesting and tax share withholding - Stock Titan
SRPT: 2026 revenue targets remain solid as clinical and commercial initiatives advance toward 2027 - TradingView
SRPT SEC FilingsSarepta Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty - TipRanks
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight - GuruFocus
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year - TipRanks
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance
Wedbush Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $29.00 - MarketBeat
Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating - marketscreener.com
Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright - MarketBeat
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Vanguard Group Inc. - MarketBeat
Sarepta (NASDAQ: SRPT) COO exercises stock options, lifts holdings to 200,750 shares - Stock Titan
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Understanding the 25.56% Upside Potential - DirectorsTalk Interviews
HC Wainwright & Co. Reiterates Sell Rating for SRPT | SRPT Stock News - GuruFocus
Sarepta Therapeutics 10-K: $2.20B Revenue, $(7.13) EPS - TradingView
Sarepta (NASDAQ: SRPT) details 2025 gene therapy setbacks and big siRNA deal - Stock Titan
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 - Yahoo Finance
Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy LaunchAnd What's Next - Yahoo Finance
Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey
Is Sarepta Therapeutics (SRPT) Pricing Reflect Its Value After Recent Share Price Slide - simplywall.st
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Sarepta (SRPT) COO earns 1,875 PSUs tied to performance milestones - Stock Titan
Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $38.00 - MarketBeat
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Erste Asset Management GmbH Has $50.59 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Announces Call for Applications for the 9 - Business Wire
Sarepta Therapeutics CEO Ingram to retire by year end - The Mighty 790 KFGO
Sarepta Therapeutics Announces Planned CEO Leadership Transition - The Globe and Mail
Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative - simplywall.st
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings - MarketBeat
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral - BioSpace
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates - Nasdaq
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO - Pharmaceutical Executive
Sarepta CEO Ingram Steps Down As Dystrophy Strikes Close To Home - Citeline News & Insights
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Sarepta to present Duchenne therapy data at MDA conference By Investing.com - Investing.com South Africa
Sarepta to present Duchenne therapy data at MDA conference - Investing.com
Sarepta seeks new boss amid Doug Ingram retirement - The Pharma Letter
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):